Nanofiltered human C1 inhibitor concentrate Cinry

Authors: Katherine A LysengWilliamson

Publish Date: 2013/07/20

Volume: 29, Issue: 9, Pages: 260-267

PDF Link

Abstract

Intravenous nanofiltered human C1 inhibitor concentrate Cinryze® is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema HAE In clinical trials in patients with HAE including some patients who were pregnant treatment with intravenous Cinryze® 1000 U effectively relieved HAE attacks Preprocedural prevention with the agent reduced the incidence of HAE attacks during and after a variety of dental surgical or interventional diagnostic procedures Routine preventative treatment every 3 or 4 days with the agent reduced the number and severity of HAE attacks In clinical trials intravenous Cinryze® was well tolerated with no cases of viral transmission being reportedThis article was updated from BioDrugs 201125531727 31 The preparation of these reviews was not supported by any external funding During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the articles Changes results from comments received were made by the author on the basis of scientific and editorial merit

Keywords: